Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study

Initial combination therapy with epoprostenol and bosentan in patients with severe PAH is associated with improvements in important outcomes such as functional class, exercise capacity, and hemodynamics. This combination strategy might also favorably affect overall and transplant-free survival.